Skip to content
Search
EN

Uganda Cuts Glimepiride Price by 69 Percent

The monthly price fell from US$7.74 to US$2.40; projected savings could fund therapy for about 24,500 patients annually.

Uganda Cuts Glimepiride Price by 69 Percent
Clintonhealthaccess
Verified Source

Clintonhealthaccess

View Original Report
3 min readRead in Indonesian

Uganda cut the price of glimepiride, an essential drug for type 2 diabetes, by 69 percent, from about US$7.74 to US$2.40 per patient per month. The reduction lowered treatment costs and could expand access, especially as national demand rose from about 3,600 packs in 2023/24 to more than 66,000 packs in 2025/26—an increase of more than 1,700 percent in two years. According to the Clinton Health Access Initiative (CHAI), the move was led by Uganda’s Ministry of Health and National Medical Stores (NMS), with technical support from CHAI and funding from The Leona M. and Harry B. Helmsley Charitable Trust.

Clinical policy met procurement strategy

Type 2 diabetes is a chronic condition in which the body cannot properly control blood sugar levels. In 2023, Uganda’s Ministry of Health revised its clinical guidelines, making glimepiride the only available second-line treatment for type 2 diabetes at primary healthcare facilities. The new guidelines replaced older sulfonylureas, which were associated with weight gain and hypoglycemia, or dangerously low blood sugar. The ministry also added glimepiride to the national clinical guidelines and Essential Medicines List.

The policy change increased demand for the drug, but the former price of about US$7.74 per patient per month threatened public budgets. If maintained as demand rose, that price could increase the risk of stockouts and out-of-pocket costs for patients. To address this, NMS combined orders from across Uganda into one national forecast large enough to meet manufacturers’ minimum order quantities. The step was designed to ensure that expanding diabetes services was not limited by the purchasing scale of individual facilities.

From price negotiation to treatment expansion

CHAI helped identify a quality-assured product through a local supplier while providing technical support and market information. The supplier complied with the Buy Uganda Build Uganda policy, which prioritizes goods from local suppliers in public procurement. CHAI also provided an “access price” estimate, a medicine cost benchmark that NMS used to guide negotiations. After screening bidders, NMS established a long-term framework contract setting supply terms over time.

As a result, the facility price fell from about US$7.74 to US$2.40 per patient per month. NMS now plans to purchase about 293,000 packs in 2026/27, more than four times the amount purchased the previous year. Although the price fell, national spending on glimepiride is projected to rise from US$512,000 to about US$703,000 because procurement volume will be much larger. At the former price, the same volume would cost about US$2.3 million; the price cut is projected to save Uganda’s public health system about US$1.6 million annually.

For patients, the savings are projected to fund about 227,000 additional months of treatment compared with the previous year. That amount is enough to keep about 24,500 patients on therapy for a full year. For healthcare managers, the framework contract also strengthened procurement certainty, supply security, and demand planning. The policy’s benefit is therefore not only a lower unit price, but also the ability to convert savings into stock and continuity of treatment.

The model works on both the supply and demand sides: the government consolidates needs, while quality suppliers and contracting mechanisms help create more predictable prices and supply. This type of market-shaping approach has been used for HIV, tuberculosis, and malaria medicines, then applied to noncommunicable diseases. Uganda’s experience shows that the approach can help make essential medicines for noncommunicable diseases more affordable and sustainable. The main lesson is clear: clinical policy and medicine access strategies must move together; changing guidelines without affordable supply can burden budgets and patients, while low-cost procurement without clinical policy does not automatically expand appropriate use.

Topics

Kementerian Kesehatan UgandaUgandadiabetes tipe 2glimepiride